Abstract:Noha Nafee, 1, 2 Dina M Gaber, 3 Alaa Abouelfetouh, 4, 5 Mustafa Alseqely, 4 Martin Empting, 6 Marc Schneider 7 1 Department of Pharmaceutics, College of Pharmacy, Kuwait University, Safat, 13110, Kuwait; 2 Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; 3 Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, 1029, Egypt; 4 Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; 5 Department of Microbiology and Immunology, Faculty of Pharmacy, Alamein International University, Alamein, 5060335, Egypt; 6 Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Department of Antiviral and Antivirulence Drugs (AVID), Saarland University, Saarbrücken, 66123, Germany; 7 Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, 66123, Germany Correspondence: Noha Nafee, Department of Pharmaceutics, College of Pharmacy, Kuwait University, Safat, 13110, Kuwait, Tel +96524634914 ; +96560300583, Fax +96524636843, Email Introduction: Cystic fibrosis (CF) is associated with pulmonary Pseudomonas aeruginosa infections persistent to antibiotics. Methods: To eradicate pseudomonal biofilms, solid lipid nanoparticles (SLNs) loaded with quorum-sensing-inhibitor (QSI, disrupting bacterial crosstalk), coated with chitosan (CS, improving internalization) and immobilized with alginate lyase (AL, destroying alginate biofilms) were developed. Results: SLNs (140– 205 nm) showed prolonged release of QSI with no sign of acute toxicity to A549 and Calu-3 cells. The CS coating improved uptake, whereas immobilized-AL ensured > 1.5-fold higher uptake and doubled SLN diffusion across the artificial biofilm sputum model. Respirable microparticles comprising SLNs in carbohydrate matrix elicited aerodynamic diameters MMAD (3.54, 2.48 μm) and fine-particle-fraction FPF (65, 48%) for anionic and cationic SLNs, respectively. The antimicrobial and/or antibiofilm activity of SLNs was explored in Pseudomonas aeruginosa reference mucoid/nonmucoid strains as well as clinical isolates. The full growth inhibition of planktonic bacteria was dependent on SLN type, concentration, growth medium, and strain. OD measurements and live/dead staining proved that anionic SLNs efficiently ceased biofilm formation and eradicated established biofilms, whereas cationic SLNs unexpectedly promoted biofilm progression. AL immobilization increased biofilm vulnerability; instead, CS coating increased biofilm formation confirmed by 3D-time lapse confocal imaging. Incubation of SLNs with mature biofilms of P. aeruginosa isolates increased biofilm density by an average of 1.5-fold. CLSM further confirmed the binding and uptake of the labeled SLNs in P. aeruginosa biofilms. Considerable uptake of CS-coated SLNs in non-mucoid strains could be observed presumably due to interaction of chitosan with LPS glycolipids in the outer cell membrane of P. aeruginosa . Conclusion: The biofilm-destructive potential of QSI/SLNs/AL inhalation is promising for site-specific biofilm-targeted interventional CF therapy. Nevertheless, the intrinsic/extrinsic fundamentals of nanocarrier–biofilm interactions require further investigation. Keywords: alginate lyase, chitosan, solid lipid nanoparticles, cystic fibrosis, Pseudomonas aeruginosa , quorum-sensing inhibitors Around 75% of adult cystic fibrosis (CF) patients suffer from the invasion of mucoid, alginate-producing strains of Pseudomonas aeruginosa that wreaks havoc upon the airways leading to accelerated deterioration of pulmonary function and ending in substantial morbidity. 1 The mucoid phenotype of P. aeruginosa – being pathognomonic for the disease – poses multiple challenges to effective treatment. Pathogenicity traits allowing P. aeruginosa to endure, proliferate, and profoundly affect all stages of CF pulmonary disease can be predicated by multiple virulence factors and biofilm formation. In addition to the mechanical stability of mature P. aeruginosa biofilms persisting in the respiratory tract, alginate overproduction is involved in the establishment of microcolonies at the beginning of biofilm formation, in addition to mechanical stability of mature P. aeruginosa biofilms persisting in the respiratory tract. P. aeruginosa biofilm is a self-produced matrix of polysaccharides (eg, alginate), proteins, nuclei -Abstract Truncated-

Carboxylated Nanoparticle Surfaces Enhance Association with Mucoid Pseudomonas aeruginosa Biofilms

Ultrasound-Launched Targeted Nanoparticle Enhances Antibacterial Sonodynamic Therapy for Effective Eradication of Pseudomonas Aeruginosa Biofilm

Ultrasound-Activatable Phase-Shift Nanoparticle As a Targeting Antibacterial Agent for Efficient Eradication Ofpseudomonas Aeruginosabiofilms

Farnesol and Selected Nanoparticles (Silver, Gold, Copper, and Zinc Oxide) as Effective Agents Against Biofilms Formed by Pathogenic Microorganisms

Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?

Bactericidal Anti-Adhesion Potential Integrated Polyoxazoline/Silver Nanoparticle Composite Multilayer Film with Ph Responsiveness

Nanocomposites against Pseudomonas aeruginosa biofilms: Recent advances, challenges, and future prospects

Nanocarriers with conjugated antimicrobials to eradicate pathogenic biofilms evaluated in murine in vivo and human ex vivo infection models

Biofilm-Sensitive Photodynamic Nanoparticles for Enhanced Penetration and Antibacterial Efficiency

Surface-functionalization effects on uptake of fluorescent polystyrene nanoparticles by model biofilms

Integrated Biofilm Dispersion and Virulence Responsiveness for Targeted Treatment of Pseudomonas aeruginosa Infection in Lungs

Engineered organic nanoparticles to combat biofilms

A Nanocomposite Hydrogel for Co-Delivery of Multiple Anti-Biofilm Therapeutics to Enhance the Treatment of Bacterial Biofilm-Related Infections.

Elaboration on the architecture of pH-sensitive surface charge-adaptive micelles with enhanced penetration and bactericidal activity in biofilms

Sugar-powered nanoantimicrobials for combating bacterial biofilms

Codelivery of synergistic antimicrobials with polyelectrolyte nanocomplexes to treat bacterial biofilms and lung infections

Development of pH-responsive nanocomposites with remarkably synergistic antibiofilm activities based on ultrasmall silver nanoparticles in combination with aminoglycoside antibiotics

Drug-loaded adhesive microparticles for biofilm prevention on oral surfaces

Liposome encapsulated surfactant abetted copper nanoparticles alleviates biofilm mediated virulence in pathogenic Pseudomonas aeruginosa and MRSA

Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms

Synergic Antibiofilm Effect of Thymol and Zinc Oxide Nanoparticles Conjugated with Thiosemicarbazone on Pathogenic Pseudomonas aeruginosa Strains